Non-formulary sacubitril-valsartan (Entresto) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by or in consultation with a cardiologist
- Documented heart failure diagnosis on the Problem List
- Left ventricular ejection fraction (LVEF; measurement of the percent of blood leaving your heart each time it contracts) less than 40%
- Receiving target dose or maximally tolerated dose* of beta-blocker, unless intolerant or contraindicated
- Receiving target dose or maximally tolerated dose* of an ACE-inhibitor or ARB, unless intolerant or contraindicated, and therapy will be replaced by sacubitril-valsartan
- No history of angioedema (swelling of the skin)
- Dose Change Only: Patient previously met criteria and is already taking the drug.

<table>
<thead>
<tr>
<th>Beta-Blocker</th>
<th>Target Dose</th>
<th>ACE-Inhibitors</th>
<th>Target Dose</th>
<th>ARB</th>
<th>Target Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carvedilol</td>
<td>25 mg BID or 50 mg BID if over 85 kg</td>
<td>Lisinopril</td>
<td>20-40 mg Daily</td>
<td>Losartan</td>
<td>100 mg Daily</td>
</tr>
<tr>
<td>Bisoprolol</td>
<td>10 mg Daily</td>
<td>Enalapril</td>
<td>10-20 mg BID</td>
<td>Valsartan</td>
<td>160 mg BID</td>
</tr>
<tr>
<td>Metoprolol succinate (XL)</td>
<td>200 mg Daily</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACE=angiotensin-converting enzyme; ARB=angiotensin-receptor blocker; BID=twice daily

*maximally tolerated dose = chart documentation of an adverse reaction to a higher dose or chart documentation of increased likelihood of adverse reaction if dose was increased. Adverse reactions may include but not limited to hypotension, bradycardia, or renal dysfunction.

1.10.19 cps

kp.org